Biocept Stock News

Gainers Avenue Therapeutics, Inc. (NASDAQ: ATXI) shares climbed 106.3% to close at $9.15. Avenue Therapeutics recently received the official meeting minutes from the FDA regarding a meeting conducte

Gainers Avenue Therapeutics, Inc. (NASDAQ: ATXI) shares surged 159.9% to $9.15. Avenue Therapeutics recently received the official meeting minutes from the FDA regarding a meeting conducted for IV T

InnovAge Holding Corp. (INNV) delivered earnings and revenue surprises of -200% and 0.74%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

HealthEquity (HQY) delivered earnings and revenue surprises of -2.94% and 1.35%, respectively, for the quarter ended July 2022. Do the numbers hold clues to what lies ahead for the stock?

RVL Pharmaceuticals PLC (RVLP) delivered earnings and revenue surprises of 20.83% and 0.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

OncoCyte (OCX) delivered earnings and revenue surprises of 46.15% and 17.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

On Friday, 61 companies hit new 52-week lows. Areas of Interest About Today's 52-Week Lows: Ecopetrol (NYSE:EC) was the biggest company in terms of market cap to set a new 52-week low. ThermoGenesis

Biocept Inc (NASDAQ:BIOC) and Plus Therapeutics Inc have announced a comprehensive laboratory services agreement for Plus Therapeutics' ReSPECT-LM trial for the treatment of cancer in the membranes t

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC) management will hold a conference call today, June 7, 2022, beginning at 4:00 p.m. Eastern time to discuss its re-focused and rationalized busi

Biocept Inc (NASDAQ:BIOC) posted first-quarter results that saw its revenue jump 12% year-over-year on the back of its RT-PCR coronavirus (COVID-19) testing services. For the period ended March 31, 2

Biocept, Inc. has reported a strong rise in full-year 2021 revenue due to growth in volumes for reverse transcription (RT) PCR coronavirus (COVID-19) testing.  The company, a leading provider of mole

Biocept Inc (NASDAQ:BIOC) has reported unaudited net revenue of $61.2 million for the financial year ending December 31, 2021.  The company also said that it had cash and cash equivalents of about

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Amylyx Says FDA Committee Casts Negative Vote On ALS Drug Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)

SAN DIEGO--(BUSINESS WIRE)---- $BIOC--Biocept to report 2021 fourth quarter and full year financial results on March 30, 2022.

Biocept (BIOC) has appointed Philippe Marchand as Chief Operating Officer, effective Mar. 08, 2022.Dr